A-Synuclein

Neuroimaging evidence of glymphatic system dysfunction in possible REM sleep behavior disorder and Parkinson’s disease

A-Synuclein, Gut-Brain axis, iRBD /

Alpha-synucleinopathy is postulated to be central to both idiopathic rapid eye movement sleep behaviour disorder (iRBD) and Parkinson’s disease (PD). Growing evidence suggests an association between the diminished clearance of α-synuclein and glymphatic system dysfunction. However, evidence accumulating primarily based on clinical data to support glymphatic system dysfunction in patients with iRBD and PD is […]

Neuroimaging evidence of glymphatic system dysfunction in possible REM sleep behavior disorder and Parkinson’s disease Read More »

Identification of components of turmeric as potential therapeutic agents to
slow the progression of neurodegeneration in Parkinson’s disease

A-Synuclein, Diet and Exercise, Vitamins / Supplements / Nutraceuticals /

Parkinson’s disease (PD) is a neurological disorder associated with severe loss of dopaminergic neurons inthe substantia nigra. These neurons are particularly vulnerable due to increased iron and decreasedantioxidant levels with aging, constant exposure to reactive oxygen species (ROS), and the presence ofneurotoxic compounds. A literature review was compiled and published, in which we postulate that

Identification of components of turmeric as potential therapeutic agents to
slow the progression of neurodegeneration in Parkinson’s disease Read More »

Parkinson’s Disease: A Prionopathy?

A-Synuclein, Biomarkers, Gut Dysbiosis, Gut Microbiota, Gut Permeability / Leaky Gut, Gut-Brain axis /

The principal pathogenic event in Parkinson’s disease is characterized by the conformational change of α-synuclein, which form pathological aggregates of misfolded proteins, and then accumulate in intraneuronal inclusions causing dopaminergic neuronal loss in specific brain regions. Over the last few years, a revolutionary theory has correlated Parkinson’s disease and other neurological disorders with a shared

Parkinson’s Disease: A Prionopathy? Read More »

Impact of environmental toxicants exposure on gut-brain axis in Parkinson disease

A-Synuclein, Enviromental, Gut Dysbiosis, Gut-Brain axis, Parkinson's Disease, Pre-PD /

Parkinson disease (PD) is a major public health challenge as many of the current drugs used in its management provide symptomatic relieve without preventing the underlying cause of the neurodegeneration. Similarly, the non-motor complications of PD, especially the gastrointestinal tract (GIT) disturbance increases the disease burden on both the PD patient and caregivers. Different theories

Impact of environmental toxicants exposure on gut-brain axis in Parkinson disease Read More »

Gut microbiota and inflammation in
Parkinson’s disease: Pathogenetic and
therapeutic insights

A-Synuclein, Butyrate, Diet and Exercise, Gut Dysbiosis, Gut Microbiota, Parkinson's Disease, Pre-PD, Probiotics, Prebiotics and Symbiotics, Short Chain Fatty Acids /

Parkinson’s disease (PD) is a progressive neurodegenerative disease characterized by dopaminergic neuronal loss andα-synuclein (α-syn) aggregation. With the acceleration of population aging process, the incidence of PD is expected toincrease, putting a heavy burden on the whole society. Recent studies have found the alterations of gut microbiota (GM) inPD patients and the clinical relevance of

Gut microbiota and inflammation in
Parkinson’s disease: Pathogenetic and
therapeutic insights Read More »

Progression of intestinal permeability changes and alpha-synuclein expression in a mouse model of Parkinson’s disease

A-Synuclein, Gut Microbiota, Gut Permeability / Leaky Gut, Gut-Brain axis, Parkinson's Disease, Pre-PD /

Parkinson’s disease (PD) is a multifocal degenerative disorder for which there is no cure. The majority of cases are sporadic with unknown etiology. Recent data indicate that untreated patients with de novo PD have increased colonic permeability and that both de novo and premotor patients have pathological expression of α-synuclein (α-syn) in their colon. Both

Progression of intestinal permeability changes and alpha-synuclein expression in a mouse model of Parkinson’s disease Read More »

Gastrointestinal symptoms of Parkinson’s
disease: A systematic review from pathogenesis
to management

A-Synuclein, Gut Dysbiosis, Gut Permeability / Leaky Gut, Gut-Brain axis, Parkinson's Disease /

The identification of Parkinson’s disease (PD) is mainly dependent on motorsymptoms, while the non-motor symptoms exist even decades ahead of the PDdiagnosis. According to Braak’s hypothesis, the enteric plexus is the first affectedsite during the pathological development of PD, and gastrointestinal (GI) symptomsappear during the onset of the disease. Although GI symptoms decrease the lifequality

Gastrointestinal symptoms of Parkinson’s
disease: A systematic review from pathogenesis
to management Read More »

THE MICROBIOTA-GUT-BRAIN AXIS

A-Synuclein, Butyrate, Gut Permeability / Leaky Gut, Gut-Brain axis, Parkinson's Disease, Pre-PD, Short Chain Fatty Acids /

The importance of the gut-brain axis in maintaining homeostasis has long been appreciated. However,the past 15 yr have seen the emergence of the microbiota (the trillions of microorganisms withinand on our bodies) as one of the key regulators of gut-brain function and has led to the appreciationof the importance of a distinct microbiota-gut-brain axis.This axis

THE MICROBIOTA-GUT-BRAIN AXIS Read More »

Identification of alpha-Synuclein Disaggregator from Camellia sp. Insight of Molecular Docking and Molecular Dynamics Simulations

A-Synuclein, Diet and Exercise /

Misfolded protein formation and aggregation are the central hallmarks for various neurodegenerative disorders. When it comes to Parkinson’s disease (PD), alpha-synuclein (α-syn) is the culprit protein. The presence of α-syn protein in lewy bodies and lewy neurites confirmed its presence in the occurrence of PD. The protein is natively present in the soluble monomeric forms,

Identification of alpha-Synuclein Disaggregator from Camellia sp. Insight of Molecular Docking and Molecular Dynamics Simulations Read More »

Alpha-Synuclein-Specific Naturally Occurring Antibodies
Inhibit Aggregation In Vitro and In Vivo

A-Synuclein, Parkinson's Disease /

Parkinson’s disease (PD) is associated with motor and non-motor symptoms and characterized by aggregates of alpha-synuclein (αSyn). Naturally occurring antibodies (nAbs) are part of theinnate immune system, produced without prior contact to their specific antigen, and polyreactive.The abundance of nAbs against αSyn is altered in patients with PD. In this work, we biophysicallycharacterized nAbs against

Alpha-Synuclein-Specific Naturally Occurring Antibodies
Inhibit Aggregation In Vitro and In Vivo Read More »